1. The pharmacological perturbation of brain zinc impairs BDNF-related signaling and the cognitive performances of young mice.
- Author
-
Frazzini, Valerio, Granzotto, Alberto, Bomba, Manuela, Massetti, Noemi, Castelli, Vanessa, d'Aurora, Marco, Punzi, Miriam, Iorio, Mariangela, Mosca, Alessandra, Delli Pizzi, Stefano, Gatta, Valentina, Cimini, Annamaria, and Sensi, Stefano L
- Subjects
Brain ,Animals ,Mice ,Inbred C57BL ,Mice ,Zinc ,Clioquinol ,Brain-Derived Neurotrophic Factor ,Cognition ,Signal Transduction ,Neuronal Plasticity ,Male ,Inbred C57BL - Abstract
Zinc (Zn2+) is a pleiotropic modulator of the neuronal and brain activity. The disruption of intraneuronal Zn2+ levels triggers neurotoxic processes and affects neuronal functioning. In this study, we investigated how the pharmacological modulation of brain Zn2+ affects synaptic plasticity and cognition in wild-type mice. To manipulate brain Zn2+ levels, we employed the Zn2+ (and copper) chelator 5-chloro-7-iodo-8-hydroxyquinoline (clioquinol, CQ). CQ was administered for two weeks to 2.5-month-old (m.o.) mice, and effects studied on BDNF-related signaling, metalloproteinase activity as well as learning and memory performances. CQ treatment was found to negatively affect short- and long-term memory performances. The CQ-driven perturbation of brain Zn2+ was found to reduce levels of BDNF, synaptic plasticity-related proteins and dendritic spine density in vivo. Our study highlights the importance of choosing "when", "where", and "how much" in the modulation of brain Zn2+ levels. Our findings confirm the importance of targeting Zn2+ as a therapeutic approach against neurodegenerative conditions but, at the same time, underscore the potential drawbacks of reducing brain Zn2+ availability upon the early stages of development.
- Published
- 2018